Silence Therapeutics plc (NASDAQ:SLN – Get Free Report)’s share price was up 1.9% during mid-day trading on Monday . The stock traded as high as $22.89 and last traded at $22.71. Approximately 22,043 shares traded hands during trading, a decline of 90% from the average daily volume of 216,201 shares. The stock had previously closed at $22.28.
Analysts Set New Price Targets
A number of research firms recently issued reports on SLN. HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Thursday, January 18th. BMO Capital Markets assumed coverage on Silence Therapeutics in a report on Wednesday, January 31st. They set an “outperform” rating and a $67.00 price objective for the company.
Silence Therapeutics Trading Down 2.5 %
The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $17.01 and its 200-day moving average is $11.33.
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.28. Silence Therapeutics had a negative return on equity of 236.14% and a negative net margin of 151.43%. The company had revenue of $3.54 million for the quarter, compared to the consensus estimate of $3.73 million. On average, equities analysts expect that Silence Therapeutics plc will post -1.34 EPS for the current fiscal year.
Institutional Trading of Silence Therapeutics
Several hedge funds have recently bought and sold shares of SLN. Goldman Sachs Group Inc. boosted its position in Silence Therapeutics by 27.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company’s stock worth $18,350,000 after acquiring an additional 205,815 shares during the period. Citadel Advisors LLC acquired a new stake in Silence Therapeutics in the second quarter worth about $136,000. UBS Group AG grew its position in Silence Therapeutics by 4.8% in the 4th quarter. UBS Group AG now owns 69,006 shares of the company’s stock valued at $1,052,000 after buying an additional 3,191 shares in the last quarter. Morgan Stanley increased its stake in Silence Therapeutics by 36.0% during the 4th quarter. Morgan Stanley now owns 210,973 shares of the company’s stock valued at $3,217,000 after buying an additional 55,814 shares during the period. Finally, Millennium Management LLC increased its stake in Silence Therapeutics by 19.8% during the 4th quarter. Millennium Management LLC now owns 17,436 shares of the company’s stock valued at $266,000 after buying an additional 2,879 shares during the period. 64.27% of the stock is currently owned by institutional investors.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company’s mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver.